Close

pCDCAR1 CD20 h(28γ), NK (CAR-NK-2-M327-BG)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD20 chimeric antigen receptor(CAR) is constructed for the engineering of NK cells to target Human CD20. The NK cells are genetically modified through transduction with a Lentiviral vector expressing scFv of anti-CD20 antibody linked to CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of chronic lymphocytic leukemia (CLL).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD20
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • Chronic lymphocytic leukemia (CLL)
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD28-FcεRIγ
  • Discription of Signaling Cassetes
  • CD28
    CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
    FcεRIγ
    The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.

Target

  • Clone
  • rituximab
  • Host
  • Chimeric
  • Target Species
  • Human
  • Gene Name
  • membrane spanning 4-domains A1
  • Synonyms
  • B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; BA0185

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Rituximab blocks antigen binding of Ab used to derive CAR scFv.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.1 Rituximab blocks antigen binding of Ab used to derive CAR scFv.

Ramos cells (CD20þ) were incubated with the indicated rituximab concentrations (conc.) for 30 minutes, followed by incubation with PE-labeled anti-CD20 Ab (clone Leu16) or isotype control at either 4C or 37C for 30 minutes. Cells were washed and analyzed by flow cytometry to determine available CD20 binding sites as measured by PE fluorescence intensity. The panel summarizes the geometric mean fluorescence intensity (MFI) at either 4C or 37C as a function of rituximab concentration.

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data FuncS

Fig.2 Effect of rituximab on CAR T-cell function in vitro.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.2 Effect of rituximab on CAR T-cell function in vitro.

The indicated B-cell NHL cell lines were irradiated and incubated for 30 minutes at room temperature with varying rituximab concentrations (at two times the concentrations during incubation to yield the indicated final concentrations after addition of T cells).

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data Cyt

Fig.3 Effect of rituximab on CAR T-cell– mediated cytotoxicity.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.3 Effect of rituximab on CAR T-cell– mediated cytotoxicity.

The indicated 51Cr-labeled target cells were preincubated for 30 minutes with rituximab (at two times the concentrations during incubation
to yield the indicated final concentrations after the addition of T cells), and then CD8þ T cells expressing the Leu16-28-z CAR were added at the E:T ratios shown in a standard 5-hour 51Cr-release assay. Mock-transduced T cells and samples with rituximab and target cells only ("0:1") were used as negative controls.

Rufener, G. A., Press, O. W., Olsen, P., Lee, S. Y., Jensen, M. C., Gopal, A. K., Pender, B., Budde, L. E., Rossow, J. K., Green, D. J., Maloney, D. G., Riddell, S. R., & Till, B. G. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab. Cancer immunology research, 4(6), 509–519.

Complete CAR data FuncS

Fig.4 In vivo effect of rituximab on CD20 CAR T-cell function.

CAR Construction : rituximab scFv-41BB-CD28ζ Latest CAR Construction

Fig.4 In vivo effect of rituximab on CD20 CAR T-cell function.

NSG mice were injected i.v. with 5  105 rituximab-refractory Raji-ffLuc lymphoma cells, followed by one of the following treatments: no treatment, rituximab only (25 mg or 200 mg) i.p. 5 days later, 107 1.5.3-NQ-28-BBz CAR T cells only 6 days after tumor,
or rituximab 25 mg or 200 mg i.p. at 5 days followed by 107 CAR T cells at 6 days after tumor. Mice were imaged twice weekly for bioluminescence.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD20 scFv h(CD28-FcεRIγ) CARNK, pCDCAR1 (CAR-NK-2-M327-BG). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.